| Literature DB >> 34137665 |
Jeffrey R Bishop1,2, R Stephanie Huang1, Jacob T Brown3, Pawel Mroz4, Steven G Johnson5, Josiah D Allen6,7, Suzette J Bielinski8, Julie England9, Joel F Farley10, David Gregornik11, Jyothsna Giri12, Christine Kroger13, Susie E Long14, Tiana Luczak3,15, Erin J McGonagle1, Sisi Ma5, Eric T Matey16, Pinar K Mandic17, Ann M Moyer18, Wayne T Nicholson19, Natasha Petry20,21, Pamala A Pawloski22, Allyson Schlichte23, Stephen W Schondelmeyer10, Randall D Seifert3, Marilyn K Speedie24, David Stenehjem3, Robert J Straka1, Jason Wachtl25, Stephen C Waring26, Brian Van Ness27, Heather A Zierhut27, Constantin Aliferis5, Susan M Wolf28, Catherine A McCarty29, Pamala A Jacobson1.
Abstract
Several healthcare organizations across Minnesota have developed formal pharmacogenomic (PGx) clinical programs to increase drug safety and effectiveness. Healthcare professional and student education is strong and there are multiple opportunities in the state for learners to gain workforce skills and develop advanced competency in PGx. Implementation planning is occurring at several organizations and others have incorporated structured utilization of PGx into routine workflows. Laboratory-based and translational PGx research in Minnesota has driven important discoveries in several therapeutic areas. This article reviews the state of PGx activities in Minnesota including educational programs, research, national consortia involvement, technology, clinical implementation and utilization and reimbursement, and outlines the challenges and opportunities in equitable implementation of these advances.Entities:
Keywords: Minnesota; implementation; pharmacogenomics
Mesh：
Year: 2021 PMID： 34137665 PMCID： PMC8265281 DOI： 10.2217/pgs-2021-0058
Source DB: PubMed Journal: Pharmacogenomics ISSN： 1462-2416 Impact factor: 2.638